In line with this notion, CRISPR/Cas9 knockout screens indicate that AML cell lines enrich for glutamine transporters (SLC1A5, SLC38A1, and SLC38A2) and glutaminase (GLS) to supply α-KG for the TCA cycle, which has been shown to protect them against the anti-proliferative effects of the BCL-2 inhibitor ABT-199 (venetoclax) (62). Here, GLS is linked to acute myeloid leukemia.